Epigenetics and dermatological disease

Pharmacogenomics

Volumn 9, Issue 12, 2008, Pages 1835-1850

  Millington, George W M ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

atopic eczema; basal cell carcinoma; cutaneous lymphoma; epigenetics; genomic imprinting; malignant melanoma; psoriasis; squamous cell carcinoma; systemic lupus erythematosus

Indexed keywords

ARSENIC; DNA; DNA METHYLTRANSFERASE 1; DNA MODIFICATION METHYLASE CCRM; HISTONE; MICRORNA; SITE SPECIFIC DNA METHYLTRANSFERASE (ADENINE SPECIFIC); UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; CROSS REACTION; DNA METHYLATION; EPIGENETICS; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME IMPRINTING; HUMAN; MELANOMA; PATHOGENESIS; PHENOTYPE; PROMOTER REGION; PSORIASIS; REVIEW; SCLERODERMA; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; RNA INTERFERENCE; SKIN TUMOR;

EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; RNA INTERFERENCE; SITE-SPECIFIC DNA-METHYLTRANSFERASE (ADENINE-SPECIFIC); SKIN DISEASES; SKIN NEOPLASMS;

EID: 61549106928     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.12.1835     Document Type: Review

References (215)

1. Waddington CH: The epigenotype. Endeavour 1, 18-20 (1942).
2. Bjornsson HT, Fallin MD, Feinberg AP: An integrated epigenetic and genetic approach to common human disease. Trends Genet. 20(8), 350-358 (2004).
3. Grummt I, Ladurner AG: A metabolic throttle regulates the epigenetic state of rDNA. Cell 133(5), 577-580 (2008). (Pubitemid 351637625)
4. Postovit LM, Costa FF, Bischof JM et al.: The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J. Cell. Biochem. 101(4), 908-917 (2007). (Pubitemid 47040871)
5. Fraga MF, Ballestar E, Paz MF et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102(30), 10604-10609 (2005). (Pubitemid 41061601)
6. Bestor TH: The DNA methyltransferases of mammals. Hum. Mol. Genet. 9(16), 2395-2402 (2000).
7. Sasai H, Matsui Y: Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nat. Rev. Genet. 9(2), 129-140 (2008).
8. Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9(6), 465-476 (2008). (Pubitemid 351693975)
9. Bonisch C, Nieratschker SM, Orfanos NK, Hake SB: Chromatin proteomics and epigenetic regulatory circuits. Expert Rev. Proteomics 5(1), 105-119 (2008). (Pubitemid 351287745)
10. Dinger ME, Mercer TR, Mattick JS: RNAs as extracellular signaling molecules. J. Mol. Endocrinol. 40(4), 151-159 (2008).
11. Kangaspeska S, Stride B, Métivier R et al.: Transient cyclical methylation of promoter DNA. Nature 452(7183), 112-115 (2008). (Pubitemid 351355094)
12. Métivier R, Gallais R, Tiffoche C et al.: Cyclical DNA methylation of a transcriptionally active promoter. Nature 452(7183), 45-50 (2008). (Pubitemid 351355084)
13. Sonkoly E, Ståhle M, Pivarcsi A: MicroRNAs: novel regulators in skin inflammation. Clin. Exp. Dermatol. 33(3), 312-315 (2008). (Pubitemid 351550660)
14. Millington GWM: Genomic imprinting and dermatological disease. Clin. Exp. Dermatol. 31(5), 681-688 (2006).
15. Vigé A, Gallou-Kabani C, Junien C: Sexual dimorphism in non-Mendelian inheritance. Pediatr. Res. 63(4), 340-347 (2008). (Pubitemid 351450576)
16. Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 58(2), 71-96 (2008).
17. Lautenschlager S, Wulf HC, Pittelkow MR: Photoprotection. Lancet 370(9586), 528-537 (2007). (Pubitemid 47212348)
18. Menzies SW: Is sun exposure a major cause of melanoma? Yes. BMJ 337, A763 (2008).
19. Vucic EA, Brown CJ, Lam WL: Epigenetics of cancer progression. Pharmacogenomics 9(2), 215-234 (2008).
20. Issa JP: CpG-island methylation in aging and cancer. Curr. Top. Microbiol. Immunol. 249, 101-118 (2000).
21. Issa JP: Age-related epigenetic changes and the immune system. Clin. Immunol. 109(1), 103-108 (2003). (Pubitemid 37324747)
22. Mack GS: Epigenetic cancer therapy makes headway. J. Natl Cancer Inst. 98(20), 1443-1444 (2006).
23. Liu X, Wang L, Zhao K et al.: The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451(7180), 846-850 (2008). (Pubitemid 351253165)
24. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18(15), 2461-2470 (1999). (Pubitemid 29206159)
25. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG: Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80(8), 1252-1258 (1999). (Pubitemid 29264087)
26. Komatsu Y, Tomizaki KY, Tsukamoto M et al.: Cyclic hydroxamic-acid- containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 61(11), 4459-4466 (2001). (Pubitemid 32685775)
27. Yamamoto S, Yamano T, Tanaka M et al.: A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther. 10(3), 179-186 (2003). (Pubitemid 36348678)
28. Kim SH, Ahn S, Han JW et al.: Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun. 315(4), 964-970 (2004). (Pubitemid 38249397)
29. Khan ANH, Magner WJ, Tomasi TB: An epigenetic vaccine model active in the prevention and treatment of melanoma. J. Transl. Med. 5, 64 (2007).
30. Yokoyama S, Feige E, Poling LL et al.: Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res. 21(4), 457-463 (2008). (Pubitemid 351990971)
31. Zhang L, Huang J, Yang N et al.: MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA 103(24), 9136-19134 (2006). (Pubitemid 43902545)
32. Gaur A, Jewell DA, Liang Y et al.: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67(6), 2456-2468 (2007). (Pubitemid 46548930)
33. Mouret S, Baudouin C, Charveron M, Favier A, Cadet J, Douki T: Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc. Natl Acad. Sci. USA 103(37), 13765-13770 (2006). (Pubitemid 44413982)
34. Sander CS, Chang H, Hamm F: Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int. J. Dermatol. 43(5), 326-335 (2004). (Pubitemid 38714593)
35. Wittgen HG, van Kempen LC: Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res. 17(6), 400-409 (2007). (Pubitemid 350084996)
36. Sharonov A, Gustavsson T, Marguet S: Photophysical properties of 5-methylcytidine. Photochem. Photobiol. Sci. 2(4), 362-364 (2003). (Pubitemid 41646686)
37. Tommasi S, Denissenko MF, Pfeifer GP: Sunlight induces pyrimidine dimers preferentially at 5-methylcytosine bases. Cancer Res. 57(21), 4727-4730 (1997). (Pubitemid 27468976)
38. Denissenko MF, Chen JX, Tang MS, Pfeifer GP: Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl Acad. Sci. USA 94(8), 3893-3898 (1997).
39. You YH, Pfeifer GP: Similarities in sunlightinduced mutational spectra of CpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J. Mol. Biol. 305(3), 389-399 (2001).
40. Peterson EJ, Bogler O, Taylor SM: p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res. 63(20), 6579-6582 (2003). (Pubitemid 37322935)
41. Giglia-Mari G, Sarasin A: TP53 mutations in human skin cancers. Hum. Mutat. 21(3), 217-228 (2003). (Pubitemid 36292964)
42. Crowson AN: Basal cell carcinoma: biology, morphology and clinical implications. Mod. Pathol. 19(Suppl. 2), S127-S147 (2006). (Pubitemid 43172313)
43. Hemminki K, Zhang H, Czene K: Time trends and familial risks in squamous cell carcinoma of the skin. Arch. Dermatol. 139(7), 885-889 (2003). (Pubitemid 36898923)
44. Nagar S, Smith LE, Morgan WF: Characterization of a novel epigenetic effect of ionizing radiation: the death-inducing effect. Cancer Res. 63(2), 324-328 (2003). (Pubitemid 36152488)
45. Pogribny I, Raiche J, Slovack M, Kovalchuk O: Dose-dependence, sex- and tissue-specificity, and persistence of radiation-induced genomic DNA methylation changes. Biochem. Biophys. Res. Commun. 320(4), 1253-1261 (2004). (Pubitemid 38916679)
46. Turk PW, Laayoun A, Smith SS, Weitzman SA: DNA adduct 8-hydroxyl-2′- deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase. Carcinogenesis 169(5), 1253-1255 (1995).
47. Panayiotidis MI, Rancourt RC, Allen CB et al.: Hyperoxia-induced DNA damage causes decreased DNA methylation in human lung epithelial-like A549 cells. Antioxid. Redox Signal. 6(1), 129-136 (2004).
48. Ghosh P, Banerjee M, Giri AK, Ray K: Toxicogenomics of arsenic: classical ideas and recent advances. Mutat. Res. 659(3), 293-301 (2008).
49. Reichard JF, Schnekenburger M, Puga A: Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem. Biophys. Res. Commun. 352(1), 188-192 (2007). (Pubitemid 44821112)
50. Gorlin RJ, Goltz RW: Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N. Engl. J. Med. 262, 908-912 (1960).
51. Hahn H, Wicking C, Zaphiropoulous PG: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85(6), 841-851 (1996). (Pubitemid 26192135)
52. Lupi O: Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int. J. Dermatol. 46(11), 1113-1117 (2007). (Pubitemid 350055879)
53. Gailani MR, Stahle-Backdahl M, Leffell DJ: The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 14(1), 78-81 (1996). (Pubitemid 26301550)
54. Couve-Privat S, Le Bret M, Traiffort E et al.: Functional analysis of novel sonic hedgehog gene mutations identified in basal cell carcinomas from xeroderma pigmentosum patients. Cancer Res. 64(10), 3559-3565 (2004). (Pubitemid 38657932)
55. Jin Y, Martins C, Salemark L et al.: Nonrandom karyotypic features in basal cell carcinomas of the skin. Cancer Genet. Cytogenet. 131(2), 109-119 (2001). (Pubitemid 34003059)
56. Cretnik M, Musani V, Oreskovic S, Leovic D, Levanat S: The patched gene is epigenetically regulated in ovarian dermoids and fibromas, but not in basocellular carcinomas. Int. J. Mol. Med. 19(6), 875-883 (2007).
57. Wolf I, Bose S, Desmond JC et al.: Unmasking of epigenetically silent genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res. Treat. 105(2), 139-155 (2007). (Pubitemid 47366878)
58. Lodygin D, Yazdi AS, Sander CA, Herzinger T, Hermeking H: Analysis of 14-13-3s expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 22(35), 5519-5524 (2003). (Pubitemid 37072207)
59. Takeuchi T, Liang SB, Ohtsuki Y: Downregulation of expression of a novel cadherin molecule, T-cadherin, in basal cell carcinoma of the skin. Mol. Carcinog. 35(4), 173-179 (2002). (Pubitemid 36056711)
60. Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG: Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumor suppressor in basal cell carcinomas. Br. J. Dermatol. 155(6), 1154-1158 (2006). (Pubitemid 44729988)
61. Pekarsky Y, Garrison PN, Palamarchuk A et al.: Fhit is a physiological target of the protein kinase Src. Proc. Natl Acad. Sci. USA 101(11), 3775-3779 (2004). (Pubitemid 38381054)
62. Ho WL, Murphy GM: Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients Br. J. Dermatol. 158(2), 217-224 (2008).
63. Oster-Schmidt C: Two cases of squamous cell carcinoma treated with topical imiquimod 5%. J. Eur. Acad. Dermatol. Venereol. 18(1), 93-95 (2004). (Pubitemid 38159369)
64. Copcu E, Aktas A, Sisman N, Oztan Y: Thirty-one cases of Marjolins ulcer. Clin. Exp. Dermatol. 28(2), 138-141 (2003).
65. Brieger J, Schroeder P, Gosepath J, Mann WJ: Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation. Int. J. Mol. Med. 16(1), 159-164 (2005).
66. De Hertog SA, Wensveen CAH, Bastiaens MT: Relation between smoking and skin cancer. J. Clin. Oncol. 19(1), 231-238 (2001).
67. Tsai KY, Tsao H: The genetics of skin cancer: Am. J. Med. Genet. C. Semin. Med. Genet. 131C(1), 82-92 (2004). (Pubitemid 39441637)
68. Fecher LA, Cummings SD, Keefe MJ, Alani RM: Toward a molecular classification of melanoma. J. Clin. Oncol. 25(12), 1606-1620 (2007).
69. Morgan DO: The Cell Cycle: Principles of Control. New Science Press, London, UK (2006).
70. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7), 1237-1245 (1992).
71. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM: p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J. Invest. Dermatol. 122(5), 1284-1292 (2004). (Pubitemid 38651105)
72. Tyler LN, Ai L, Zuo C, Fan CY, Smoller BR: Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin. Mod. Pathol. 16(7), 660-664 (2003). (Pubitemid 36871498)
73. Arbiser JL, Fan CY, Su X et al.: Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosaassociated squamous cell carcinoma. J. Invest. Dermatol. 123(4), 788-790 (2004). (Pubitemid 39281622)
74. Murao K, Kubo Y, Ohtani N, Hara E, Arase S: Epigenetic abnormalities in cutaneous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways. Br. J. Dermatol. 155(5), 999-1005 (2006). (Pubitemid 44564511)
75. Chiles MC, Ai L, Zuo C, Fan CY, Smoller BR: E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod. Pathol. 16(10), 1014-1018 (2003). (Pubitemid 37280817)
76. Fraga MF, Herranz M, Espada J et al.: A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 64(16), 5527-5534 (2004). (Pubitemid 39095543)
77. Guerrero D, Guarch R, Ojer A et al.: Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int. 102(6), 747-755 (2008).
78. Lesniak W, Slomnicki LP, Kuznicki J: Epigenetic control of the S100A6 (calcylin) gene expression. J. Invest. Dermatol. 127(10), 2307-2314 (2008).
79. Yanagawa N, Osakabe M, Hayashi M, Tamura G, Motoyama T: Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinoma. Virchows Arch. 452(4), 377-382 (2008).
80. Bocci G, Francia G, Man S, Lawler J, Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl Acad. Sci. USA 100(22), 12917-12922 (2003). (Pubitemid 37340000)
81. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B: Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23(22), 4014-4022 (2004). (Pubitemid 38747930)
82. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS: Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 63(7), 1639-1643 (2003). (Pubitemid 36373656)
83. Reifenberger J, Knobbe CB, Sterzinger AA et al.: Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer 109(3), 377-384 (2004). (Pubitemid 38252766)
84. Dammann R, Schagdarsurengin U, Seidel C et al.: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol. Histopathol. 20(2), 645-663 (2005). (Pubitemid 40468282)
85. Ferrari S, Calabretta B, de Riel JK et al.: Structural and functional analysis of a growth-regulated gene, the human calcyclin. J. Biol. Chem. 262(17), 8325-8332 (1987). (Pubitemid 17104267)
86. McClaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW: Incidence of noncutaneous melanoma in the U.S. Cancer 103(5), 1000-1007 (2005).
87. Crotty K, McCarthy S, Mihm MC: The histological diagnosis and classification of melanoma. In: Textbook of Melanoma. Thompson JF, Morton DL, Kroon BBR (Eds). Martin Dunitz, NY, USA, 115-121 (2004).
88. Houghton AN, Polsky D: Focus on melanoma. Cancer Cell. 2(4), 275-278 (2002). (Pubitemid 41043961)
89. Shuster S: Is sun exposure a major cause of melanoma? No. BMJ 337, A764 (2008).
90. Cannon-Albright LA, Thomas A, Goldgar DE et al.: Familiality of cancer in Utah. Cancer Res. 54(9), 2378-2385 (1994). (Pubitemid 24138728)
91. Newton JA, Bataille V, Griffiths K et al.: How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J. Am. Acad. Dermatol. 29(6), 989-996 (1993). (Pubitemid 23360333)
92. Newton-Bishop JA, Harland M, Randerson- Moor J, Bishop DT: Management of familial melanoma. Lancet Oncol. 8(1), 46-54 (2007). (Pubitemid 44943090)
93. Bennett DC: How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21(1), 27-38 (2008).
94. Lo RS, Witte ON: Transforming growth factor-β activation promotes genetic context-dependent invasion of immortalised melanocytes. Cancer Res. 68(11), 4248-4257 (2008).
95. Pollock PM, Harper UL, Hansen KS et al.: High frequency of BRAF mutations in nevi. Nat. Genet. 33(1), 19-20 (2003).
96. Curtin JA, Fridlyand J, Kageshita T et al.: Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353(20), 2135-2147 (2005). (Pubitemid 41653105)
97. Cruz F, Rubin BP, Wilson D et al.: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63(18), 5761-5766 (2003). (Pubitemid 37187472)
98. Akslen LA, Puntervoll H, Bachmann IM et al.: Mutation analysis of the EGFR-NRASBRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 18(1), 29-35 (2007). (Pubitemid 351628053)
99. Millington GWM: Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin. Exp. Dermatol. 31(3), 407-412 (2006).
100. Landi MT, Bauer J, Pfeiffer RM et al.: MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313(5786), 521-522 (2006). (Pubitemid 44148456)
101. Fargnoli MC, Pike K, Pfeiffer RM et al.: MC1R variants increase risk of melanomas harboring BRAF mutations. J. Invest. Dermatol. 128(10), 2485-2490 (2008).
102. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH: High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer 111(5), 705-710 (2004). (Pubitemid 39062892)
103. Jackson S, Harland M, Turner F et al.: No evidence for BRAF as a melanoma/nevus susceptibility gene. Cancer Epidemiol. Biomarkers Prev. 14(4), 913-918 (2005). (Pubitemid 40478556)
104. Hochedlinger K, Blelloch R, Brennan C et al.: Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18(15), 1875-1885 (2004). (Pubitemid 39025097)
105. Gallagher WM, Bergin OE, Rafferty M et al.: Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26(11), 1856-1867 (2005). (Pubitemid 41631258)
106. Paz MF, Fraga MF, Avila S et al.: A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63(5), 1114-1121 (2003). (Pubitemid 36278446)
107. Gonzalgo ML, Bender CM, You EH et al.: Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 57(23), 5336-5347 (1997).
108. Fujimoto A, Morita R, Hatta N, Takehara K, Takata M: p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18, 2527-2532 (1999). (Pubitemid 29206166)
109. Dobrowolski R, Hein R, Buettner R, Bosserhoff AK: Loss of p14ARF expression in melanoma. Arch. Dermatol. Res. 293(11), 545-551 (2002).
110. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA: Significant impact of promoter hypermethylation and the 540 C > T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am. J. Pathol. 161(1), 229-237 (2002). (Pubitemid 34760788)
111. Freedberg DE, Rigas SH, Russak J et al.: Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl Cancer Inst. 100(11), 784-795 (2008). (Pubitemid 351809672)
112. Bandyopadhyay D, Curry JL, Lin Q et al.: Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell. 6(4), 577-591 (2007). (Pubitemid 47087062)
113. Weisenberger DJ, Siegmund KD, Campan M et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 38(7), 787-793 (2006). (Pubitemid 43980599)
114. Tsutsumida A, Hamada J, Tada M et al.: Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int. J. Oncol. 25(5), 1415-1421 (2004).
115. Tang A, Eller MS, Hara M et al.: E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J. Cell. Sci. 107(4), 983-992 (1994). (Pubitemid 24119356)
116. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P: Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23(30), 5215-5226 (2004). (Pubitemid 38980354)
117. Hegi ME, Diserens AC, Gorlia T et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). (Pubitemid 40349502)
118. Epping MT, Wang L, Plumb JA et al.: A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 104(45), 17777-17782 (2007). (Pubitemid 350210911)
119. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB: The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8(6), 443-454 (2005) (Pubitemid 41773448)
120. Carreira S, Goodall J, Denat L et al.: Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20(24), 3426-3439 (2006). (Pubitemid 44969160)
121. Bemis LT, Chen R, Amato CM et al.: MicroRNA-137 targets microphthalmiaassociated transcription factor in melanoma cell lines. Cancer Res. 68(5), 1362-1368 (2008). (Pubitemid 351346843)
122. Felicetti F, Errico MC, Bottero L et al.: The promyelocytic leukemia zinc fingermicroRNA- 221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 68(8), 2745-2754 (2008). (Pubitemid 351556272)
123. Molnér V, Tamési V, Bakos B, Wiener Z, Falus A: Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin. Cancer Biol. 18(2), 111-122 (2008).
124. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 18(5), 549-557 (2008). (Pubitemid 351630945)
125. Lodygin D, Tarasov V, Epanchintsev A et al.: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7(16), 2591-2600 (2008).
126. Shahrzad S, Bertrand K, Minhas K, Coomber BL: Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2(2), 119-129 (2007). (Pubitemid 351682006)
127. Govindarajan B, Sligh JE, Vincent BJ et al.: Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest 117(3), 719-729 (2007) (Pubitemid 46348530)
128. Muller DW, Bosserhoff AK: Integrin β(3) is regulated by let-7a miRNA in malignant melanoma. Oncogene 27(52), 6698-6706 (2008).
129. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93(14), 7149-7153 (1996). (Pubitemid 26243517)
130. De Smet C, Lurquin C, Lethé B, Martelange V, Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19(11), 7327-7335 (1999). (Pubitemid 29493396)
131. Sigalotti L, Coral S, Nardi G et al.: Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J. Immunother. 25(1), 16-26 (2002). (Pubitemid 34052830)
132. Mulcahy KA, Rimoldi D, Brasseur F et al.: Infrequent expression of the MAGE gene family in uveal melanomas. Int. J. Cancer 66(6), 738-742 (1996). (Pubitemid 26197940)
133. van der Velden PA, Zuidervaart W, Hurks MH et al.: Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int. J. Cancer 106(4), 472-479 (2003). (Pubitemid 36966202)
134. Moulin AP, Clément G, Bosman FT, Zografos L, Benhattar J: Methylation of CpG island promoters in uveal melanoma. Br. J. Ophthalmol. 92(2), 281-285 (2008). (Pubitemid 351224112)
135. Kirkpatrick KL, Mokbel K: The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur. J. Surg. Oncol. 27(8), 754-760 (2001). (Pubitemid 33085546)
136. Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C: Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res. 16(1), 83-87 (2006). (Pubitemid 44133056)
137. Kirkpatrick CS, White E, Lee J: Case- control study of malignant melanoma in Washington State II. Diet, alcohol, and obesity. Am. J. Epidemiol. 139(9), 869-880 (1994).
138. Oh SW, Yoon YS, Shin S: Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation study. J. Clin. Oncol. 23(21), 4742-4754 (2005). (Pubitemid 46224078)
139. Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF: Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15(1), 35-43 (2004). (Pubitemid 38339970)
140. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF: Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17(7), 901-909 (2006). (Pubitemid 44078281)
141. Dubin N, Moseson M, Pasternack BS: Epidemiology of malignant melanoma: pigmentary traits, ultraviolet radiation, and the identification of high-risk populations. Recent Results Cancer Res. 102, 56-75 (1986).
142. Veierod MB, Thelle DS, Laake P: Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int. J. Cancer 71(4), 600-604 (1997). (Pubitemid 27239370)
143. Fortes C, Mastroeni S, Melchi F et al.: A protective effect of the Mediterranean diet for cutaneous melanoma. Int. J. Epidemiol. 37(5), 1018-1029 (2008).
144. Kaput J, Perlina A, Hatipoglu B, Bartholomew A, Nikolsky Y: Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics 8(4), 369-390 (2007). (Pubitemid 46591098)
145. Slater DN: The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br. J. Dermatol. 153(5), 874-880 (2005).
146. Hwang ST, Janik JE, Jaffe ES, Wilson WH: Mycosis fungoides and Sézary syndrome. Lancet 371(9616), 945-957 (2008).
147. Sakamoto FH, Colleoni GW, Teixera SP et al.: Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma. Int. J. Dermatol. 45(4), 447-449 (2006).
148. Ellis L, Pan Y, Smyth GK et al.: Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin.Cancer Res. 14(14), 4500-4510 (2008).
149. Galm O, Herman JG, Baylin SB: The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20(1), 1-13 (2006). (Pubitemid 43106714)
150. Navas IC, Algara P, Mateo M et al.: p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. Lab. Invest. 82(2), 123-132 (2002). (Pubitemid 34160450)
151. Scarisbrick JJ, Woolford AJ, Calonje E et al.: Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome. J. Invest. Dermatol. 118(3), 493-499 (2002). (Pubitemid 34227167)
152. Scarisbrick JJ, Mitchell TJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ: Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J. Invest. Dermatol. 121(4), 894-901 (2003). (Pubitemid 37239136)
153. Gallardo F, Esteller M, Pujol RM, Costa C, Estrach T, Servitje O: Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. Haematologica 89(11), 1401-1403 (2004). (Pubitemid 39540583)
154. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA: Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Pathol. 157(4), 1137-1146 (2000).
155. van Doorn R, Zoutman WH, Dijkman R et al.: Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG and p73. J. Clin. Oncol. 23(17), 3886-3896 (2005). (Pubitemid 46218691)
156. Sommer VH, Clemmensen OJ, Nielsen O et al.: In vivo activation of STAT3 in cutaneous T-cell lymphoma: evidence for an antiapoptotic function of STAT3. Leukemia 18(7), 1288-1295 (2004). (Pubitemid 39023140)
157. Vikhanskaya F, Toh WH, Dulloo I et al.: p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat. Cell. Biol. 9(6), 698-705 (2007). (Pubitemid 47214733)
158. Kolodner RD: Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem. Sci. 20(10), 397-401 (1995).
159. Zani VJ, Asou N, Jadayel D et al.: Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. Blood 87(8), 3124-3134 (1996). (Pubitemid 26115340)
160. LaForgia S, Morse B, Levy J et al.: Receptor protein-tyrosine phosphatase γ is a candidate tumor suppressor gene at human chromosome region 3p21. Proc. Natl Acad. Sci. USA 88(11), 5036-5040 (1991). (Pubitemid 21914678)
161. Kamata T, Yamashita M, Kimura M et al.: Src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J. Clin. Invest. 111(1), 109-119, (2003). (Pubitemid 36134854)
162. Cerroni L, Zöchling N, Ptz B, Kerl H: Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J. Cutan. Pathol. 24(8), 457-461 (1997). (Pubitemid 27432373)
163. Gronbaek K, Moller PH, Nedergaard T et al.: Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br. J. Dermatol. 142(5), 913-923 (2000). (Pubitemid 30304601)
164. Child FJ, Scarisbrick JJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ: Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J. Invest. Dermatol. 118(6), 941-948 (2002). (Pubitemid 34639171)
165. Dijkman R, Tensen CP, Jordanova ES et al.: Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J. Clin. Oncol. 24(2), 296-305 (2006). (Pubitemid 46622058)
166. DCruz DP: Systemic lupus erythematosus. BMJ 332(7546), 890-894 (2006). (Pubitemid 44365587)
167. Arbuckle MR, McClain MT, Rubertone MV et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349(16), 1526-1533 (2003). (Pubitemid 37255038)
168. Deapen D, Escalante A, Weinrib L et al.: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 35(3), 311-318 (1992).
169. Jarvinen P, Aho K: Twin studies in rheumatic diseases. Semin. Arthritis Rheum. 24(1), 19-28 (1994).
170. Sanders CJG, van Weelden H, Kazzaz GAA, Sigurdsson V, Toonstra J, Bruijnzeel- Koomen CA: Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br. J. Dermatol. 149(1), 131-137 (2003). (Pubitemid 36966522)
171. Richardson BC, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33(11), 1665-1673 (1990).
172. Deng C, Kaplan MJ, Yang J et al.: Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 44(2), 397-407 (2001).
173. Zhou Y, Lu O: DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun. Rev. 7(5), 376-383 (2008).
174. Yung R, Powers D, Johnson K et al.: Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte functionassociated antigen 1 become autoreactive and cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 97(12), 2866-2871 (1996). (Pubitemid 26197100)
175. Richardson BC, Strahler JR, Pivirotto TS et al.: Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 35(6), 647-662 (1992).
176. Takeuchi T, Amano K, Sekine H, Koide J, Abe T: Up-regulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. J. Clin. Invest. 92(6), 3008-3016 (1993). (Pubitemid 24006572)
177. Lu O, Kaplan MJ, Ray D et al.: Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 46(5), 1282-1291 (2002). (Pubitemid 34525836)
178. Kaplan MJ, Lu O, Wu A, Attwood J, Richardson BC: Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J. Immunol. 172(6), 3652-3661 (2004). (Pubitemid 38337948)
179. Lu O, Wu A, Richardson BC: Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupusinducing drugs. J. Immunol. 174(10), 6212-6219 (2005). (Pubitemid 40663812)
180. Lu O, Wu A, Tesmer L, Ray D, Yousif N, Richardson BC: Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179(9), 6352-6358 (2007).
181. Mi XB, Zeng FQ: Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients. Acta Pharmacol. Sin. 29(1), 105-112 (2008).
182. Sawalha AH, Webb R, Han S et al.: Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS ONE 3(3), E1727 (2008). (Pubitemid 351903230)
183. Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarrés M: Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. J. Leukoc. Biol. 81(6), 1609-1616 (2007) (Pubitemid 46827983)
184. Krieg AM: CpG motifs in bacterial DNA and their immune effects Annu. Rev. Immunol. 20, 709-760 (2002).
185. Krieg AM, Yi AK, Matson S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374(6522), 546-549 (1995).
186. Stacey KJ, Young GR, Clark F et al.: The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 170(7), 3614-3620 (2003). (Pubitemid 36359230)
187. Krieg AM, Vollmer J: Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 220, 251-269 (2007). (Pubitemid 350045572)
188. Klinman D, Shirota H, Tross D, Sato T, Klaschik S: Synthetic oligonucleotides as modulators of inflammation. J. Leukoc. Biol. 84(4), 958-964 (2008).
189. Lee PP, Lee TL, Ho MH, Wong WH, Lau YL: Recurrent major infections in juvenile-onset systemic lupus erythematosus - a close link with long-term disease damage. Rheumatology (Oxford) 46(8), 1290-1296 (2007).
190. Wang Y, Fan PS, Kahaleh B: Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54(7), 2271-2279 (2006). (Pubitemid 44051084)
191. Mayes MD, Trojanowska M: Genetic factors in systemic sclerosis. Arthritis Res. Ther. 9(Suppl. 2), S5 (2007).
192. Luo Y, Li Y, Su Y et al.: Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus. Br. J. Dermatol. 159(4), 827-833 (2008).
193. Mishra N, Brown DR, Olorenshaw IM et al.: Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-g gene and protein expression in lupus T cells. Proc. Natl Acad. Sci. USA 98(5), 2628-2633 (2001). (Pubitemid 32209533)
194. Hu N, Qiu X, Luo Y et al.: Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 35(5), 804-810 (2008). (Pubitemid 351747120)
195. Dieker JW, Fransen JH, van Bavel CC et al.: Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum. 56(6), 1921-1933 (2007).
196. van Ghelue M, Moens U, Bendiksen S, Rekvig OP: Autoimmunity to nucleosomes related to viral infection: a focus on hapten-carrier complex formation. J. Autoimmun. 20(2), 171-182 (2003) (Pubitemid 36355842)
197. Lebwohl M: Psoriasis. Lancet 361(9364), 1197-1204 (2003). (Pubitemid 36398393)
198. Smith CH, Barker JNWN: Psoriasis and its management. BMJ 333(7564), 380-384 (2006).
199. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE: Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. 62(3), 229-236 (1982). (Pubitemid 12112914)
200. Duffy DL, Spelman LS, Martin NG: Psoriasis in Australian twins. J. Am. Acad. Dermatol. 29(3), 428-434 (1993).
201. Elias AN, Barr RJ, Nanda VS: p16 expression in psoriatic lesions following therapy with propylthiouracil, an antithyroid thioureylene. Int. J. Dermatol. 43(12), 889-892 (2004).
202. Chen M, Chen ZQ, Cui PG et al.: The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. Br. J. Dermatol. 158(5), 987-993 (2008). (Pubitemid 351521461)
203. Zhang K, Zhang R, Li X, Yin G, Niu X, Hou R: The mRNA expression and promoter methylation status of the p16 gene in colony-forming cells with high proliferative potential in patients with psoriasis. Clin. Exp. Dermatol. 32(6), 702-708 (2007). (Pubitemid 47609729)
204. Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, Hirankarn N, Mutirangura A: SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J. Mol. Med. 84(2), 175-182 (2006). (Pubitemid 43201258)
205. Sehra S, Tuana FM, Holbreich M et al.: Scratching the surface: towards understanding the pathogenesis of atopic dermatitis. Crit. Rev. Immunol. 28(1), 15-43 (2008). (Pubitemid 351264073)
206. Nakamura T, Sekigawa I, Ogasawara H: Expression of DNMT-1 in patients with atopic dermatitis. Arch. Dermatol. Res. 298(5), 253-256 (2006). (Pubitemid 44394520)
207. Saldanha G, Fletcher A, Slater DN: Basal cell carcinoma: a dermatopathological and molecular biological update. Br. J. Dermatol. 148(2), 195-202 (2003). (Pubitemid 36278957)
208. Pielop JA, Brownell I, Duvic M: Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int. J. Dermatol. 42(2), 116-122 (2003). (Pubitemid 41709840)
209. Eggermann T, Eggermann K, Schönherr N: Growth retardation versus overgrowth: Silver-Russell syndrome is genetically opposite to Beckwith-Wiedemann syndrome. Trends Genet. 24(4), 195-204 (2008).
210. Saunthararajah Y, Molokie R, Saraf S et al.: Clinical effectiveness of decitabine in severe sickle cell disease. Br. J. Haematol. 141(1), 126-129 (2008). (Pubitemid 351347540)
211. Zheng Y, Thompson PR, Cebrat M et al.: Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol. 376, 188-199 (2004). (Pubitemid 38200179)
212. Iyer NG, Ozdag H, Caldas C: p300/CBP and cancer. Oncogene 23(24), 4225-4231 (2004). (Pubitemid 38758588)
213. Valentini A, Gravina P, Federici G, Bernadini S: Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol. Ther. 6(2), E1-E7 (2007). (Pubitemid 46641621)
214. Becker JC, Kirkwood JM, Agarwala SS, Drummer R, Schrama D, Hauschild A: Molecularly targeted therapy for melanoma: current reality and future options. Cancer 23(10), 2317-2327 (2006). (Pubitemid 44748514)
215. Hauschild A, Trefzer U, Garbe C et al.: Multicentre Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N- {4-[(2-aminophenyl)-carbamoyl]- benzyl}- carbamate in pretreated metastatic melanoma. Melanoma Res. 18(4), 274-278 (2008).